{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:48:11Z","timestamp":1782470891939,"version":"3.54.5"},"posted":{"date-parts":[[2026,6,24]]},"group-title":"Neurology","reference-count":32,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Network hyperexcitability is increasingly implicated in prodromal Alzheimer\u2019s disease and may be suppressed by antiseizure medications (ASMs). ASMs are widely prescribed to older adults, yet whether their use relates to Alzheimer\u2019s-disease biomarkers at the population level is unknown. In 52,537 participants in the National Alzheimer\u2019s Coordinating Center (NACC) study, we compared cerebrospinal-fluid biomarkers, amyloid and tau positron emission tomography (PET) between ASM users and non-users using inverse-probability-of-treatment weighting with gradient-boosted propensity scores. ASM users showed directionally lower amyloid across multiple brain regions, amplifying markedly in APOE \u03b54 carriers (Centiloid \u03b2 = \u221225.7, p = 0.007). All three temporal tau-PET composites were significantly lower in users (META-temporal \u03b2 = \u22120.05, p = 0.01). The amyloid finding replicated independently in the the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) dataset (Centiloid \u03b2 = \u22128.6, p = 0.01), whereas four comparator drug classes showed no amyloid signal. These convergent observational findings provide a quantitative framework for evaluating ASMs as candidate disease-modifying agents in Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.64898\/2026.06.22.26356204","type":"posted-content","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:20:20Z","timestamp":1782321620000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of antiseizure medication with lower amyloid and tau burden"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-7163","authenticated-orcid":false,"given":"Carolina","family":"Ferreira-Atuesta","sequence":"first","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-7544","authenticated-orcid":false,"given":"Kai Michael","family":"Schubert","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Noain","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Draganski","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Inselspital, University Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-071X","authenticated-orcid":false,"given":"Marian","family":"Galovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026062602550671000_2026.06.22.26356204v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2026062602550671000_2026.06.22.26356204v1.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206171109"},{"key":"2026062602550671000_2026.06.22.26356204v1.3","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5215-08.2009"},{"key":"2026062602550671000_2026.06.22.26356204v1.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0198"},{"key":"2026062602550671000_2026.06.22.26356204v1.5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp3984"},{"key":"2026062602550671000_2026.06.22.26356204v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2005.10.028"},{"key":"2026062602550671000_2026.06.22.26356204v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2801"},{"key":"2026062602550671000_2026.06.22.26356204v1.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1162844"},{"key":"2026062602550671000_2026.06.22.26356204v1.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121081109"},{"key":"2026062602550671000_2026.06.22.26356204v1.10","doi-asserted-by":"crossref","unstructured":"Nygaard, H. B. et al. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer\u2019s disease mouse model. Alzheimers Res. Ther. 7, 25 (2015).","DOI":"10.1186\/s13195-015-0110-9"},{"key":"2026062602550671000_2026.06.22.26356204v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2013.15"},{"key":"2026062602550671000_2026.06.22.26356204v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4328"},{"key":"2026062602550671000_2026.06.22.26356204v1.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131685"},{"key":"2026062602550671000_2026.06.22.26356204v1.14","doi-asserted-by":"crossref","unstructured":"Delbono, O. , Wang, Z.-M. & Messi, M. L . The rise and deceleration of neuronal excitability in aging and Alzheimer\u2019s disease: Mechanisms, implications, and therapeutic targets. Ageing Res. Rev. 114, 102999 (2026).","DOI":"10.1016\/j.arr.2025.102999"},{"key":"2026062602550671000_2026.06.22.26356204v1.15","doi-asserted-by":"crossref","unstructured":"Targa Dias Anastacio, H. , Matosin, N. & Ooi, L. Neuronal hyperexcitability in Alzheimer\u2019s disease: what are the drivers behind this aberrant phenotype? Transl. Psychiatry 12, 257 (2022).","DOI":"10.1038\/s41398-022-02024-7"},{"key":"2026062602550671000_2026.06.22.26356204v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.046"},{"key":"2026062602550671000_2026.06.22.26356204v1.17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24794"},{"key":"2026062602550671000_2026.06.22.26356204v1.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209920"},{"key":"2026062602550671000_2026.06.22.26356204v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2014.06.009"},{"key":"2026062602550671000_2026.06.22.26356204v1.20","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011310040008"},{"key":"2026062602550671000_2026.06.22.26356204v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.03.023"},{"key":"2026062602550671000_2026.06.22.26356204v1.22","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1002\/trc2.70004","article-title":"The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE \u03b54 non-carriers with mild cognitive impairment due to Alzheimer\u2019s disease","volume":"10","year":"2024","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv"},{"key":"2026062602550671000_2026.06.22.26356204v1.23","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/epi4.13070","article-title":"Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer\u2019s disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trial","volume":"9","year":"2024","journal-title":"Epilepsia Open"},{"key":"2026062602550671000_2026.06.22.26356204v1.24","doi-asserted-by":"publisher","DOI":"10.64898\/2026.05.20.26353714"},{"key":"2026062602550671000_2026.06.22.26356204v1.25","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318142774e"},{"key":"2026062602550671000_2026.06.22.26356204v1.26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2177-05.2005"},{"key":"2026062602550671000_2026.06.22.26356204v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2016.141"},{"key":"2026062602550671000_2026.06.22.26356204v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30044-3"},{"key":"2026062602550671000_2026.06.22.26356204v1.29","first-page":"886","article-title":"Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer\u2019s disease pathogenesis. Nat","volume":"6","year":"2026","journal-title":"Aging"},{"key":"2026062602550671000_2026.06.22.26356204v1.30","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4040-10.2010"},{"key":"2026062602550671000_2026.06.22.26356204v1.31","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"2026062602550671000_2026.06.22.26356204v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.01.021"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.22.26356204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:55:20Z","timestamp":1782467720000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.06.22.26356204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":32,"URL":"https:\/\/doi.org\/10.64898\/2026.06.22.26356204","relation":{},"subject":[],"published":{"date-parts":[[2026,6,24]]},"subtype":"preprint"}}